Morgan Stanley raised its holdings in Boston Scientific Co. (NYSE:BSX) by 114.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,517,384 shares of the medical equipment provider’s stock after buying an additional 4,013,765 shares during the quarter. Morgan Stanley owned about 0.54% of Boston Scientific worth $245,818,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in BSX. Captrust Financial Advisors increased its holdings in shares of Boston Scientific by 103.8% in the second quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 1,594 shares during the period. Somerset Group LLC increased its holdings in shares of Boston Scientific by 3.4% in the second quarter. Somerset Group LLC now owns 49,838 shares of the medical equipment provider’s stock valued at $1,630,000 after purchasing an additional 1,638 shares during the period. Bainco International Investors increased its holdings in shares of Boston Scientific by 0.8% in the second quarter. Bainco International Investors now owns 208,514 shares of the medical equipment provider’s stock valued at $6,818,000 after purchasing an additional 1,729 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of Boston Scientific by 2.7% in the first quarter. Commonwealth Equity Services LLC now owns 71,279 shares of the medical equipment provider’s stock valued at $1,947,000 after purchasing an additional 1,850 shares during the period. Finally, Mutual of America Capital Management LLC increased its holdings in shares of Boston Scientific by 0.9% in the second quarter. Mutual of America Capital Management LLC now owns 218,066 shares of the medical equipment provider’s stock valued at $7,131,000 after purchasing an additional 1,876 shares during the period. Institutional investors own 90.91% of the company’s stock.
Boston Scientific stock opened at $37.39 on Friday. The stock has a market cap of $50.39 billion, a P/E ratio of 26.22, a P/E/G ratio of 2.53 and a beta of 0.63. Boston Scientific Co. has a 52 week low of $24.54 and a 52 week high of $37.72. The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62.
In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $32.42, for a total value of $162,100.00. Following the sale, the executive vice president now directly owns 29,201 shares of the company’s stock, valued at $946,696.42. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Michael F. Mahoney sold 116,666 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $35.88, for a total value of $4,185,976.08. Following the completion of the sale, the chairman now directly owns 2,023,104 shares in the company, valued at $72,588,971.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 175,250 shares of company stock worth $6,196,995. 0.73% of the stock is owned by corporate insiders.
A number of research analysts have recently weighed in on BSX shares. Zacks Investment Research lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, May 18th. TheStreet raised Boston Scientific from a “c” rating to an “a-” rating in a report on Tuesday, May 29th. ValuEngine lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, June 1st. Argus increased their price objective on Boston Scientific from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, June 7th. Finally, Sanford C. Bernstein started coverage on Boston Scientific in a report on Wednesday, June 27th. They issued an “outperform” rating and a $38.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and three have assigned a strong buy rating to the stock. Boston Scientific currently has a consensus rating of “Buy” and an average price target of $36.18.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.